¼¼°èÀÇ CRISPR ±â¹Ý Áø´Ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
CRISPR-Based Diagnostics Market Size, Share & Trends Analysis Report By Product (Enzymes, Kits & Reagents, Software & Libraries), By Technology (Cas9, Cas12), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1750865
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,158,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,529,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,271,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ CRISPR ±â¹Ý Áø´Ü ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

Grand View Research, IncÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ CRISPR ±â¹Ý Áø´Ü ½ÃÀå ±Ô¸ð´Â 2025-2030³â±îÁö 16.57%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ±â·ÏÇØ 2030³â 75¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î Cas È¿¼ÒÀÇ °³¹ßÀº CRISPR ±â¹Ý Áø´Ü °Ë»çÀÇ ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Çâ»ó ½ÃÄ×½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸·Î º´¿øÃ¼¿Í À¯ÀüÀÚ µ¹¿¬º¯À̸¦ ³ôÀº Á¤È®µµ·Î °¨Áö ÇÒ ¼öÀÖ´Â ½Å¼ÓÇÑ Æ÷ÀÎÆ® ¿Àºê Äɾî(POC) Áø´Ü µµ±¸ÀÇ °³¹ßÀÌ ÃËÁøµÇ¾ú½À´Ï´Ù.

½ÃÀå ±Ô¸ðÀÇ ±ÞÁõÀº ÇコÄɾî ÁöÃâ Áõ°¡, À¯ÀüÀÚ ÆíÁý ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸¸¼º ÁúȯÀ̳ª À¯Àü¼º ÁúȯÀÇ ¸¸¿¬ µîÀÇ ¿äÀο¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù. °áÇÙÀº ¿©ÀüÀÌ ¼¼°è¿¡¼­ 2¹øÂ°·Î ¸¹Àº °¨¿°ÁõÀ̸ç, 2023³â¿¡´Â ÃßÁ¤ 1,080¸¸¸íÀÌ °áÇÙÀ¸·Î Áø´ÜµÇ¾ú´Ù°í º¸°íÇϰí ÀÖ½À´Ï´Ù.

À¯Àü¼º Áúȯ°ú Àü¿°º´ÀÇ ¼¼°è¿¡ ÀÖ´Â ÀÌȯÀ² Áõ°¡´Â Áøº¸µÈ Áø´Ü °ø±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁõÆø½Ã۰í ÀÖ½À´Ï´Ù. ±¹Á¦¾Ï ¿¬±¸±â°ü¿¡ µû¸£¸é ¼¼°èÀÇ ½Å±Ô¾Ï ȯÀÚ¼ö´Â 2025³â 2,130¸¸¸í¿¡¼­ 2050³â 3,530¸¸¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. À¯»çÇϰÔ, 2024³â 8¿ù¿¡ Lancet ÀâÁö¿¡ °ÔÀçµÈ ¿¬±¸´Â ºñÀ¯·´°è ÁÖ¹Î, ƯÈ÷ Àεµ ¾Æ´ë·ú¿¡¼­ ³¶Æ÷¼º ¼¶À¯ÁõÀÇ À¯º´·üÀÌ ¿¹»óº¸´Ù ³ô´Ù´Â °ÍÀ» ¹àÇû½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀº CRISPR ±â¹Ý °Ë»ç¿Í °°Àº ´Ù¾çÇÑ Áúº´ÀÇ Á¶±â ¹ß°ß ¹× Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â Á¤¹ÐÇÏ°í ½Å¼ÓÇÑ Áø´Ü ¹æ¹ýÀÇ Çʿ伺À» °­Á¶ÇÕ´Ï´Ù. ƯÁ¤ À¯ÀüÀÚ ¼­¿­À» Á¤È®ÇÏ°Ô È®ÀÎÇÏ´Â CRISPR Áø´ÜÀÇ ´É·ÂÀº À¯Àü¼º Áúȯ°ú °¨¿°À¸·Î ÀÎÇÑ ºÎ´ã Áõ°¡¿¡ ´ëóÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

Áö¿ªÀûÀ¸·Î CRISPR ±â¹Ý Áø´Ü ½ÃÀåÀº ´Ù¾çÇÑ ¼ºÀå ÆÐÅÏÀ» º¸¿©ÁÝ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÇöÀç °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí Àִµ¥, ÀÌ´Â Àü¿°º´ÀÇ À¯Çà°ú °Ç°­ °ü¸® ÀÎÇÁ¶ó ÅõÀÚ Áõ°¡·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ÇÑÆí, ºÏ¹Ì´Â R&D ÅõÀÚÀÇ Ãæ½Ç°ú ÷´Ü Áø´Ü ±â¼úÀÇ Á¶±â µµÀÔÀ¸·Î °¡Àå ±Þ¼ºÀåÇÏ´Â Áö¿ªÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 9¿ù, Sherlock Biosciences´Â ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º(HPV) °ËÃâÀ» À§ÇÑ CRISPR ±â¼úÀ» Ȱ¿ëÇÑ ½Å¼ÓÇÏ°í ±â±¸°¡ ÇÊ¿ä ¾ø´Â ºÐÀÚÁø´Ü¹ýÀÇ °³¹ßÀ» °­È­Çϱâ À§ÇØ Bill & Melinda Gates FoundationÀ¸·ÎºÎÅÍ Ãß°¡ ÀÚ±ÝÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌ´Ï¼ÅÆ¼ºê´Â °øÁß º¸°Ç ¹®Á¦ ÇØ°á¿¡ CRISPR ±â¼úÀ» Ȱ¿ëÇÏ·Á´Â Áö¿ªÀÇ ³ë·ÂÀ» ¹Ý¿µÇÕ´Ï´Ù.

CRISPR ±â¹Ý Áø´Ü ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀå : Á¦Ç°º°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦5Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀå : ±â¼úº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦6Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀå : ¿ëµµº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦7Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦8Àå CRISPR ±â¹Ý Áø´Ü ½ÃÀå : Áö¿ªº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦9Àå °æÀï ±¸µµ

>JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

CRISPR-based Diagnostics Market Growth & Trends:

The global CRISPR-based diagnostics market size is expected to reach USD 7.55 billion by 2030, registering a CAGR of 16.57% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological innovations have been pivotal in propelling the CRISPR diagnostics market forward. The development of novel Cas enzymes, such as Cas12 and Cas13, has enhanced the sensitivity and specificity of CRISPR-based diagnostic tests. These advancements have facilitated the creation of rapid, point-of-care (POC) diagnostic tools capable of detecting pathogens and genetic mutations with high accuracy. In August 2023, Indian biotech startup CrisprBits collaborated with Molbio Diagnostics to develop CRISPR-based POC tests. This partnership led to the creation of the PathCrisp platform, designed for rapid and precise disease detection, and has been instrumental in expanding the availability of CRISPR diagnostics in resource-limited settings. Such collaborations exemplify how technological advancements are translating into practical diagnostic solutions.

The surge in market size is attributed to factors such as increased healthcare spending, heightened demand for gene editing technologies, and a growing prevalence of chronic and genetic diseases. For instance, the World Health Organization reported in 2024 that tuberculosis (TB) remained the second most common infectious disease worldwide, with an estimated 10.8 million people diagnosed in 2023 Such statistics underscore the pressing need for advanced diagnostic tools such as CRISPR-based tests.

The increasing incidence of genetic disorders and infectious diseases globally has amplified the demand for advanced diagnostic tools. According to the International Agency for Research on Cancer, the number of new cancer cases worldwide is expected to rise from 21.3 million in 2025 to 35.3 million by 2050. Similarly, research published in The Lancet in August 2024 highlighted a higher-than-expected prevalence of cystic fibrosis in non-European populations, particularly in the Indian subcontinent. These trends underscore the necessity for precise and rapid diagnostic methods, such as CRISPR-based tests, which can facilitate early detection and treatment of various diseases. The ability of CRISPR diagnostics to accurately identify specific genetic sequences makes them invaluable in managing the growing burden of genetic and infectious diseases.

Geographically, the CRISPR diagnostics market exhibits varying growth patterns. Asia Pacific currently holds the largest market share, driven by a high prevalence of infectious diseases and increasing investments in healthcare infrastructure. Conversely, North America is projected to be the fastest-growing region, attributed to substantial research and development investments and early adoption of advanced diagnostic technologies. For instance, in September 2023, Sherlock Biosciences received additional funding from the Bill & Melinda Gates Foundation to enhance the development of rapid, instrument-free molecular diagnostics leveraging CRISPR technology for Human Papillomavirus (HPV) detection . Such initiatives reflect the regional efforts to harness CRISPR technology in addressing public health challenges.

CRISPR-based Diagnostics Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. CRISPR-Based Diagnostics Market Variables, Trends, & Scope

Chapter 4. CRISPR-Based Diagnostics Market: Product Estimates & Trend Analysis

Chapter 5. CRISPR-Based Diagnostics Market: Technology Estimates & Trend Analysis

Chapter 6. CRISPR-Based Diagnostics Market: Application Estimates & Trend Analysis

Chapter 7. CRISPR-Based Diagnostics Market: End Use Estimates & Trend Analysis

Chapter 8. CRISPR-Based Diagnostics Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â